Navigation Links
BSGI Offers Improved Cancer Detection for Negative or Indeterminate Mammograms
Date:6/3/2010

NEWPORT NEWS, Va., June 3 /PRNewswire/ -- Researchers at the Legacy Good Samaritan Hospital in Portland, Oregon presented data on the clinical use of Breast-Specific Gamma Imaging (BSGI), a molecular breast imaging technique, at the American Society of Breast Surgeons Annual meeting in Las Vegas in April: Breast Specific Gamma Imaging Used As An Adjunct to Mammography.  

664 patients were involved in the retrospective review where BSGI was evaluated as part of the diagnostic work-up of patients that had presented with abnormal mammographic or ultrasound imaging, physical exam, significant family or personal breast cancer history or dense breasts. Overall, the sensitivity was 85 percent with a specificity of 81 percent. The positive predictive value (PPV) was 68 percent and the negative predictive value was 81 percent. Using the Breast Imaging Reporting and Data System (BI-RADS), the PPV for BI-RADS 1-3 of 30% compares favorably with the expected BI-RADS prediction of <2 percent malignancy rate for this category. In the BI-RADS 4-6 group, the PPV increased considerably to 86%.

Dr. Nathalie Johnson, Medical Director of Cancer Services at Legacy Good Samaritan Hospital, and principal investigator on the study, concluded, "BSGI is a useful adjunct in the imaging work-up of breast patients and has a high sensitivity and specificity. It is best used to further evaluate unclear mammographic or ultrasound findings, as the positive predictive value is highest in this setting. However, in high-risk patients with BI-RADS 1-3, it will improve cancer detection significantly."

Overall, mammography and BSGI were both positive in 144 cancers. BSGI was positive in 23 cancers which were negative by mammography. However, there were 26 cancers positive on mammography and negative on BSGI. In short, BSGI can improve breast cancer detection in patients with normal or indeterminate mammograms, but should not be used to obviate the need for biopsy in patients with positive mammographic findings.

For the study, BSGI was conducted using a Dilon 6800®, a digital high-resolution, breast-optimized gamma camera. With BSGI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells absorb a greater amount of the tracing agent than the normal surrounding tissue and generally appear as dark spots on the BSGI image.

About Dilon Diagnostics

Dilon Diagnostics, a brand of Dilon Technologies Inc., is bringing innovative medical imaging products to market. Dilon's cornerstone product, the Dilon 6800, is a digital high-resolution, compact gamma camera optimized to perform BSGI, a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering BSGI to their patients, including: Cornell University Medical Center, New York; George Washington University Medical Center, Washington, D.C.; and The Rose, Houston. For more information on Dilon Diagnostics please visit www.dilon.com.


'/>"/>
SOURCE Dilon Diagnostics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. RediClinic Offers Affordable New Plan Clinically Shown to Double a Persons Chance to Stop Smoking
2. Spine Institute of Louisiana Offers Cervical Spine Motion Preservation as an Alternative to Fusion Surgery
3. CVS/pharmacy Offers Flu Vaccinations in Over 4,000 Stores
4. Spit for the Cure Offers Unique Opportunity for Women to Participate in Breast Cancer Research
5. Concentra Offers Flu Vaccines to Keep America Working
6. New Report by Pediatricians Finds Gaps in Preparing to Protect Kids From Pandemic Flu, Offers Recommendations
7. UPDATE: New Report by Pediatricians Finds Gaps in Preparing to Protect Kids From Pandemic Flu, Offers Recommendations
8. New UNAIDS Report Offers Encouraging News, But Most HIV-Positive Mothers Still Not Getting the Care & Treatment They Need
9. New Data Published in The Lancet Show GSKs ROTARIX(R) Offers Protection Against the Most Common Circulating Rotavirus Types
10. Researcher Investigates Disparities in Doctor-Patient Information Exchange During Clinical Trial Offers
11. New Report Offers Hope for Closing Health Gap for African Americans, With Nearly 700 Medicines in Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017   ZappRx, Inc ., a ... drug prescribing process, today announced it closed $25 million in ... venture capital firm based in Seattle ... Venture Partners . The Series B round included participation from ... in 2014, and GV (formerly Google Ventures). As ...
(Date:4/20/2017)... 2017 Research and Markets has announced ... Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive ... offering. ... market was valued at US$ 7,167.6 Mn in 2015, and ... at a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... ... Getting enough sleep affects much more than energy – it also has mental and physical ... compromise motor reaction time, which can increase the risk of having a car accident. ... from the NSF to help you sleep better and feel better:, , ...
(Date:4/28/2017)... ... ... The Radiology Business Management Association (RBMA) is pleased to announce its ... has been in place since the RBMA was founded in 1968 with all board ... Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson the chief executive officer for Clinical ...
(Date:4/28/2017)... ... April 28, 2017 , ... From April ... of Urgent Care Medicine will host industry leaders for the annual spring Convention ... those in the industry adapt to the issues currently affecting urgent care and ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... which name the Creator responds to and which He does not. Yisrayl says with ... which one is the true name, but he says with a little Scripture, backed with ...
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation Limited, a ... its Nova Skin Sciences division, recently announced the launch of Allumière Antiaging Cream, ... power of an anti-aging concentrate. , Anogeissus Leiocarpa Bark Extract and ...
Breaking Medicine News(10 mins):